Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Psychopharmacology (Berl) ; 236(2): 641-655, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30377748

ABSTRACT

Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease. The present study investigated the effects of 50 and 100 mg/kg berberine (BRB) on recognition memory, oxidative stress, and purinergic neurotransmission, in a model of sporadic dementia of the Alzheimer's type induced by intracerebroventricular (ICV) injection of streptozotocin (STZ) in rats. Rats were submitted to ICV-STZ 3 mg/kg or saline, and 3 days later, were started on a treatment of BRB or saline for 21 days. The results demonstrated that BRB was effective in protecting against memory impairment, increased reactive oxygen species, and the subsequent increase in protein and lipid oxidation in the cerebral cortex and hippocampus, as well as δ-aminolevulinate dehydratase inhibition in the cerebral cortex. Moreover, the decrease in total thiols, and the reduced glutathione and glutathione S-transferase activity in the cerebral cortex and hippocampus of ICV-STZ rats, was prevented by BRB treatment. Besides an antioxidant effect, BRB treatment was capable of preventing decreases in ecto-nucleoside triphosphate diphosphohydrolase (NTPDase), 5'-nucleotidase (EC-5'-Nt), and adenosine deaminase (ADA) activities in synaptosomes of the cerebral cortex and hippocampus. Thus, our data suggest that BRB exerts a neuroprotective effect on recognition memory, as well as on oxidative stress and oxidative stress-related damage, such as dysfunction of the purinergic system. This suggests that BRB may act as a promising multipotent agent for the treatment of AD.


Subject(s)
Berberine/pharmacology , Brain/drug effects , Neuroprotective Agents/pharmacology , Oxidative Stress/drug effects , Recognition, Psychology/drug effects , 5'-Nucleotidase/drug effects , 5'-Nucleotidase/metabolism , Adenosine Deaminase/drug effects , Adenosine Deaminase/metabolism , Alzheimer Disease/psychology , Animals , Antibiotics, Antineoplastic/toxicity , Antioxidants , Brain/metabolism , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Disease Models, Animal , Glutathione , Glutathione Transferase/drug effects , Glutathione Transferase/metabolism , Hippocampus/drug effects , Hippocampus/metabolism , Injections, Intraventricular , Lipid Metabolism/drug effects , Male , Memory/drug effects , Memory Disorders/chemically induced , Oxidation-Reduction/drug effects , Pyrophosphatases/drug effects , Pyrophosphatases/metabolism , Rats , Rats, Wistar , Reactive Oxygen Species/metabolism , Streptozocin/toxicity , Synaptosomes/drug effects , Synaptosomes/enzymology
2.
Neurotoxicology ; 57: 241-250, 2016 12.
Article in English | MEDLINE | ID: mdl-27746125

ABSTRACT

The present study aimed to investigate the effects of berberine (BRB) on spatial and learning memory, anxiety, acetylcholinesterase activity and cell death in an experimental model of intracerebroventricular streptozotocin (ICV-STZ) induced sporadic Alzheimer's-like dementia. Sixty male Wistar rats were randomly divided into six groups: control (CTR), BRB 50mg/kg (BRB 50), BRB 100mg/kg (BRB 100), streptozotocin (STZ), streptozotocin plus BRB 50mg/kg (STZ+BRB 50), and streptozotocin plus BRB 100mg/kg (STZ+BRB 100). Rats were injected with ICV-STZ (3mg/kg) or saline, and daily oral BRB treatment began on day 4 for a period of 21days. Behavioral tests were carried out on day 17, and rats were euthanized on day 24. Cell death analysis and determination of acetylcholinesterase activity was performed on the cerebral cortex and hippocampus of the brain. Administration of BRB prevented the memory loss, anxiogenic behavior, increased acetylcholinesterase activity and cell death induced by ICV-STZ. This may be explained, in part, by a protective effect of BRB on ameliorating the progression of neurodegenerative diseases, including Alzheimer's disease, and the results of this study provide a better understanding of the effect of BRB on the brain. Thus, BRB may act as a potential neuroprotective agent.


Subject(s)
Alzheimer Disease/complications , Anxiety/drug therapy , Berberine/therapeutic use , Memory Disorders/drug therapy , Neuroprotective Agents/therapeutic use , Acetylcholinesterase/metabolism , Alzheimer Disease/chemically induced , Alzheimer Disease/pathology , Animals , Antibiotics, Antineoplastic/administration & dosage , Anxiety/etiology , Body Weight/drug effects , Brain/drug effects , Brain/metabolism , Brain/pathology , Cell Death/drug effects , Disease Models, Animal , Dose-Response Relationship, Drug , Exploratory Behavior/drug effects , L-Lactate Dehydrogenase/metabolism , Male , Maze Learning/drug effects , Memory Disorders/etiology , Rats , Rats, Wistar , Streptozocin/administration & dosage , Synaptosomes/drug effects , Synaptosomes/ultrastructure
SELECTION OF CITATIONS
SEARCH DETAIL
...